Technology evaluation: electroporation therapy, Genetronics Inc

Area of Science:

• Biomedical Engineering
• Oncology
• Medical Devices

Background:

• Systemic administration of cytotoxic drugs often leads to severe side effects.
• Intracellular drug delivery is a key challenge in cancer chemotherapy.
• Electroporation therapy offers a novel approach to targeted drug delivery.

Purpose of the Study:

• To evaluate the efficacy and safety of electroporation therapy in cancer treatment.
• To assess the potential of electroporation for enhanced intracellular accumulation of anticancer drugs.
• To report clinical outcomes of electroporation therapy in patients with cutaneous and subcutaneous tumors.

Main Methods:

• Development of the MedPulser device and needle array applicator for electroporation.
• Combination of electric pulses with intratumoral injections of anticancer drugs (e.g., bleomycin).
• Conducting preclinical and clinical studies, including Phase II trials for various cancers.

Main Results:

• Electroporation therapy enables intracellular drug accumulation, bypassing systemic toxicity.
• Objective responses observed in a Phase II study of head and neck cancer patients (1999).
• Minimal side effects reported in clinical studies across multiple cancer types.

Conclusions:

• Electroporation therapy is a promising approach for targeted cancer treatment.
• The technique facilitates effective drug delivery with an improved safety profile.
• Further clinical trials are warranted to establish its role in standard cancer care.